ITCI — Intra-Cellular Therapies Share News
0.000.00%
Last trade - 00:00- $14.04bn
- $13.04bn
- $680.85m
Intra-Cellular Therapies Inc reports results for the quarter ended in September - Earnings Summary
Brief: Intra-Cellular Therapies Q3 Net Income USD -24.3 Million
Intra-Cellular Therapies Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results
Intra-Cellular Therapies Inc reports results for the quarter ended in June - Earnings Summary
Brief: Intra-Cellular Therapies Q2 Net Income USD -42.8 Million
Intra-Cellular Therapies Inc expected to post a loss of 59 cents a share - Earnings Preview
Intra-Cellular Therapies Inc reports results for the quarter ended in March - Earnings Summary
Brief: Intra-Cellular Therapies Q1 net loss USD 44.1 million
Brief: Intra-Cellular Therapies Reports First Quarter 2023 Financial Results
Intra-Cellular Therapies Inc expected to post a loss of 61 cents a share - Earnings Preview
Intra-Cellular's antipsychotic drug sales to remain strong in 2023 - MS
U.S. RESEARCH ROUNDUP- Enliven Therapeutics, Lululemon Athletica, Walgreens
U.S. RESEARCH ROUNDUP-Etsy, Qualtrics International, Tcr2 Therapeutics
Intra-Cellular Therapies Inc reports results for the quarter ended in December - Earnings Summary
Brief: Intra-Cellular Therapies Reports Q4 Net Loss Of $0.45 Per Share
Brief: Intra-Cellular Therapies Posts Q4 Revenue USD 87.869 Million
Intra-Cellular Therapies Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: Intra-Cellular Therapies Says Entered Into New Supply Agreement With Siegfried AG